Anti-cancer potential of a novel SERM ormeloxifene

Current Medicinal Chemistry

Volumn 20, Issue 33, 2013, Pages 4177-4184

  Gara, Rishi Kumar ^a   Sundram, Vasudha ^a   Chauhan, Subhash C ^a,b   Jaggi, Meena ^a,b  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Breast cancer; Cancer; Chemo resistance; Chronic myeloid leukemia; Contraceptive; Head and neck squamous cell carcinoma; Ormeloxifene; Ovarian cancer; Prostate cancer; SERM

Indexed keywords

CENTCHROMAN; DOXORUBICIN; ESTROGEN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; MIFEPRISTONE; PERTUZUMAB; QUERCETIN; RESVERATROL; TAMOXIFEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIGRATION; NONHUMAN; OVARY CANCER; PROSTATE CANCER; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPYRANS; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84887884997     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990197     Document Type: Article

References (57)

1. Singh, M.M. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormonerelated clinical disorders. Med. Res. Rev., 2001, 21(4), 302-347.
2. Lal, J. Clinical pharmacokinetics and interaction of centchroman-a mini review. Contraception, 2010, 81(4), 275-280.
3. Singh, M.M.; Kamboj, V.P. Fetal resorption in rats treated with an antiestrogen in relation to luteal phase nidatory estrogen secretion. Acta. Endocrinol.(Copenh.), 1992, 126(5), 444-450.
4. Misra, N.C.; Nigam, P.K.; Gupta, R.; Agarwal, A.K.; Kamboj, V.P. Centchroman-a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study. Int. J. Cancer, 1989, 43(5), 781-783.
5. Nigam, M.; Singh, N.; Ranjan, V.; Zaidi, D.; Sharma, R.; Nigam, D.; Gupta, D.K.; Sundaram, S.; Balapure, A.K. Centchroman mediated apoptosis involves cross-talk between extrinsic/intrinsic pathways and oxidative regulation. Life Sci., 2010, 87(23-26), 750-758.
6. Nigam, M.; Ranjan, V.; Srivastava, S.; Sharma, R.; Balapure, A.K. Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells. Life Sci., 2008, 82(11-12), 577-590.
7. Shenoy, B.D.; Udupa, N.; Kamath, R.; Devi, P.U. Evaluation of anti-tumor efficacy of injectable Centchroman in mice bearing Ehrlich ascites carcinoma. Indian J. Physiol. Pharmacol., 1999, 43(2), 259-262.
8. Srivastava, V.K.; Gara, R.K.; Bhatt, M.L.; Sahu, D.P.; Mishra, D.P. Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR pathway. Biochem. Biophys. Res. Commun., 2011, 404(1), 40-45.
9. Gupta, S.; Mukhopadhyay, A.; Ray, S.; Giri, A.K. Comparative antimutagenic effects of D-and L-centchroman and their comparison with tamoxifen in Salmonella assay. Mutat. Res., 1999, 445(1), 1-8.
10. Roy, S.; Kumari, G.L.; Madoiya, K.; Prakash, V.; Ray, S. Induction of ovulation in the human with centchroman: a preliminary report. Fertil. Steril., 1976, 27(9), 1108-1110.
11. Seth, R.K.; Kole, P.L.; Sarin, J.P. Studies on Centchroman, a new antifertility compound. Indian J. Pharm. Sci., 1983, 45(1), 14-16.
12. Ray, S.; Grover, P.K.; Kamboj, V.P.; Setty, B.S.; Kar, A.B.; Anand, N. Antifertility agents. 12. Structure-activity relationship of 3,4-diphenylchromenes and-chromans. J. Med. Chem., 1976, 19(2), 276-279.
13. Roy, S.; Datta, J.K. Nature of estrogenic and anti-estrogenic actions of centchroman on rat uterus. Contraception, 1976, 13(5), 597-604.
14. Mehrotra, P.K.; Karkun, J.N.; Kar, A.B. Estrogenicity of some nonsteroidal compounds. Contraception, 1973, 7(2), 115-124.
15. Datta, J.K.; Roy, S. Effect of centchroman on morphological and biochemical changes induced by testosterone propionate in uterus of rats. Indian J. Exp. Biol., 1979, 17(10), 1061-1063.
16. Nair, R.K.; Sheyte, T.A.; Munshi, S.R. Progestational & antiprogestational effects of Centchroman in mouse & rabbit. Indian J. Exp. Biol., 1977, 15(12), 1157-1158.
17. Chandra, H.; Srimal, R.C.; Kamboj, V.P.; Dhawan, B.N.; Gupta, N.N. Clinical pharmacology studies with Centchroman. Indian J. Exp. Biol., 1977, 15(12), 1170-1172.
18. Khurana, M.; Lal, J.; Singh, M.M.; Paliwal, J.K.; Kamboj, V.P.; Gupta, R.C. Evaluation of interaction potential of certain concurrently administered drugs with pharmacological and pharmacokinetic profile of centchroman in rats. Contraception, 2002, 66(1), 47-56.
19. Srivastava, A.K.; Agnihotri, A.; Kamboj, V.P. Binding of centchroman-a nonsteroidal antifertility agent to human plasma proteins. Experientia, 1984, 40(5), 465-466.
20. Mishra, N.; Ratna, S.; Ray, S.; Roy, S. Distribution and excretion pattern of 14C-labeled centchroman in the rhesus monkeys. Med. Sci. Res., 1992, 20, 259-260.
21. Ratna, S.; Mishra, N.; Ray, S.; Roy, S. Centchroman: Tissue distribution and excretion profile in albino rats after oral and intravenous administration. J. Basic. Appl. Biomed., 1994, 2, 31-34.
22. Paliwal, J.K.; Gupta, R.C. Tissue distribution and pharmacokinetics of centchroman. A new nonsteroidal postcoital contraceptive agent and its 7-desmethyl metabolite in female rats after a single oral dose. Drug Metab. Dispos., 1996, 24(2), 148-155.
23. Lal, J.; Asthana, O.P.; Nityanand, S.; Gupta, R.C. Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception, 1995, 52(5), 297-300.
24. Paliwal, J.K.; Grover, P.K.; Asthana, O.P.; Nityanand, S.; Gupta, R.C. Excretion of centchroman in breast milk. Br. J. Clin. Pharmacol., 1994, 38(5), 485-486.
25. Gupta, R.C.; Nityanand, S.; Asthana, O.P.; Lal, J. Pharmacokinetics of Centchroman in Nursing Women and Passage into Breast Milk. Clin. Drug Invest., 1996, 11(5), 305-309.
26. Lal, J.; Nityanand, S.; Asthana, O.P.; Gupta, R.C. Multiple-dose pharmacokinetics of centchroman in female volunteers. Indian J. Pharmacol., 1998, 30, p120.
27. Singh, M.M.; Chauhan, S.C.; Trivedi, R.N.; Maitra, S.C.; Kamboj, V.P. Correlation of pinopod development on uterine luminal epithelial surface with hormonal events and endometrial sensitivity in rat. Eur. J. Endocrinol., 1996, 135(1), 107-117.
28. Chauhan, S.C.; Singh, M.M.; Maitra, S.C.; Kamboj, V.P. Inhibition of progesterone-induced development of giant mitochondria in uterine glandular epithelial cells by an antiestrogen in rat. Contraception, 1996, 54(4), 259-264.
29. Arbatti, N.J.; Sheth, A.R.; Vaidya, R.A. Effect of L-dopa on Centchroman induced prolactin levels in female rats. Indian J. Exp. Biol., 1977, 15(12), 1193-1194.
30. Arbatti, N.J.; Sheth, A.R.; Vaidya, R.A. Mode of action of Centchroman on hypothalamo-pituitary axis in male rats. Indian J. Exp. Biol., 1977, 15(12), 1194-1195.
31. Saha Roy, S.; Vadlamudi, R.K. Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast Cancer, 2012, 2012 ,Article ID 654698.
32. Lim, E.; Metzger-Filho, O.; Winer, E.P. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park), 2012, 26(8), 688-694.
33. Thomas, C.; Gustafsson, J.A. The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer, 2011, 11(8), 597-608.
34. Dwivedi, A.; Basu, R.; Chowdhury, S.R.; Goyal, N. Modulation of estrogen action during preimplantation period and in immature estradiol-primed rat uterus by anti-implantation agent, ormeloxifene. Contraception, 2005, 71(6), 458-464.
35. O'Connor, P.M.; Jackman, J.; Bae, I.; Myers, T.G.; Fan, S.; Mutoh, M.; Scudiero, D.A.; Monks, A.; Sausville, E.A.; Weinstein, J.N.; Friend, S.; Fornace, A.J., Jr.; Kohn, K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growthinhibitory potency of 123 anticancer agents. Cancer Res., 1997, 57(19), 4285-4300.
36. Singh, N.; Zaidi, D.; Shyam, H.; Sharma, R.; Balapure, A.K. Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to Centchroman. PLoS One, 2012, 7(6), e37736.
37. Yallapu, M.M.; Maher, D.M.; Sundram, V.; Bell, M.C.; Jaggi, M.; Chauhan, S.C. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian. Res., 2010, 3(11).
38. Mishra, R.; Tiwari, A.; Bhadauria, S.; Mishra, J.; Murthy, P.K.; Murthy, P.S. Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[alpha]anthracene-induced breast tumor in rat. Food Chem. Toxicol., 2010, 48(6), 1587-1591
39. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin., 2012, 62(1), 10-29.
40. Ho, S.-M.; Leung, Y.-K.; Chung, I. Estrogens and Antiestrogens as Etiological Factors and Therapeutics for Prostate Cancer. Ann. N. Y. Acad. Sci., 2006, 1089(1), 177-193.
41. Lissoni, P.; Vigano, P.; Vaghi, M.; Frontini, L.; Giuberti, C.; Manganini, V.; Casu, M.; Brivio, F.; Niespolo, R.; Strada, G. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res., 2005, 25(5), 3597-3599.
42. Clarke, B.L.; Khosla, S. Modulators of androgen and estrogen receptor activity. Crit. Rev. Eukaryot. Gene Expr., 2010, 20(4), 275-294.
43. Mimeault, M.; Venkatraman, G.; Johansson, S.L.; Moore, E.; Henichart, J.P.; Depreux, P.; Lin, M.F.; Batra, S.K. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int. J. Cancer, 2007, 120(1), 160-169.
44. Rossi, V.; Bellastella, G.; De Rosa, C.; Abbondanza, C.; Visconti, D.; Maione, L.; Chieffi, P.; Della Ragione, F.; Prezioso, D.; De Bellis, A.; Bellastella, A.; Sinisi, A.A. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor alpha and beta. J. Cell. Physiol., 2011, 226(5), 1334-1339.
45. Matta, A.; Ralhan, R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol., 2009, 1(6).
46. Schuller, D.E.; Abou-Issa, H.; Parrish, R. Estrogen and progesterone receptors in head and neck cancer. Arch. Otolaryngol., 1984, 110(11), 725-727.
47. Shatalova, E.G.; Klein-Szanto, A.J.P.; Devarajan, K.; Cukierman, E.; Clapper, M.L. Estrogen and Cytochrome P450 1B1 Contribute to Both Early-and Late-Stage Head and Neck Carcinogenesis. Cancer Prev. Res., 2011, 4(1), 107-115.
48. Egloff, A.M.; Rothstein, M.E.; Seethala, R.; Siegfried, J.M.; Grandis, J.R.; Stabile, L.P. Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res., 2009, 15(21), 6529-6540.
49. Alonso, L.; Gallego, E.; Gonzalez, F.J.; Sanchez-Munoz, A.; Torres, E.; Pajares, B.I.; Leeflang, S.; Baha, C. Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study. Clin. Transl. Oncol., 2009, 11(11), 748-752.
50. Lavie, O.; Longacre, T.; Segev, Y.; Husain, A. Ovarian carcinosarcomas associated with prolonged use of tamoxifen: case reports. Int. J. Gynecol. Cancer, 2009, 19(9), 1521-1523.
51. Vermorken, J.B.; Hoekman, K. Chemotherapy for gynecologic malignancies. Curr. Opin. Oncol., 1995, 7(5), 457-465.
52. Bendrik, C.; Karlsson, L.; Dabrosin, C. Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer. Cancer Lett., 2010, 292(1), 32-40.
53. Mullen, P.; Cameron, D.A.; Hasmann, M.; Smyth, J.F.; Langdon, S.P. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol. Cancer Ther., 2007, 6(1), 93-100.
54. Faratian, D.; Zweemer, A.J.; Nagumo, Y.; Sims, A.H.; Muir, M.; Dodds, M.; Mullen, P.; Um, I.; Kay, C.; Hasmann, M.; Harrison, D.J.; Langdon, S.P. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin. Cancer Res., 2011, 17(13), 4451-4461.
55. Devalapally, H.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer, 2007, 121(8), 1830-1838.
56. Pal, P.; Kanaujiya, J.K.; Lochab, S.; Tripathi, S.B.; Bhatt, M.L.; Singh, P.K.; Sanyal, S.; Trivedi, A.K. 2-D gel electrophoresisbased proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562. Proteomics, 2011, 11(8), 1517-1529.
57. Cao, Y.; DePinho, R.A.; Ernst, M.; Vousden, K. Cancer research: past, present and future. Nat. Rev. Cancer, 2011, 11(10), 749-754.